top of page
Search

Hyperlipidemia (High Cholesterol): What Every Patient Needs to Know

  • Aug 21
  • 13 min read

August 21, 2026

Introduction

Nearly 86 million American adults are carrying total cholesterol levels above the healthy range, and most feel completely fine. High cholesterol, medically known as hyperlipidemia, is one of the most common conditions doctors diagnose, and also one of the most misunderstood. It causes no pain, no obvious symptoms, and no warning signs, yet it quietly builds up damage inside your arteries year after year. The good news is that hyperlipidemia is also one of the most controllable risk factors in all of medicine. With the right diet, activity level, and, when needed, medication, most people can bring their numbers into a healthy range and meaningfully lower their risk of heart attack and stroke.

What Is Hyperlipidemia?

Cholesterol is a waxy, fat-like substance your body needs to build cells and make hormones. It travels through your bloodstream packaged inside particles called lipoproteins. Low-density lipoprotein, or LDL, is often called 'bad' cholesterol because too much of it can stick to artery walls and form plaque. High-density lipoprotein, or HDL, is often called 'good' cholesterol because it helps carry excess cholesterol away from the arteries and back to the liver for disposal.

Think of your arteries like household pipes. A small amount of buildup on the inside walls does not stop water flow, but over years, grease and residue accumulate, narrowing the pipe until flow slows or blocks entirely. LDL cholesterol behaves the same way inside your arteries, gradually narrowing the passageway blood needs to reach your heart and brain. Hyperlipidemia simply means your cholesterol levels, particularly LDL, are high enough to accelerate that buildup.

Epidemiology

According to the CDC's most recent National Health and Nutrition Examination Survey data (August 2021 to August 2023), about 86 million U.S. adults age 20 and older have total cholesterol above 200 mg/dL, and roughly 25 million have total cholesterol at or above 240 mg/dL, the threshold considered high. The prevalence of high total cholesterol overall is about 11.3 percent, with no major difference between men and women, though it peaks in middle age: 6.0 percent for ages 20 to 39, 16.7 percent for ages 40 to 59, and 11.3 percent for those 60 and older.


More than one-quarter of U.S. adults have LDL cholesterol above 130 mg/dL, and low HDL cholesterol, which raises cardiovascular risk on its own, affects about 14.2 percent of adults overall, more commonly in men (21.8 percent) than women (6.8 percent). Of the adults who could benefit from cholesterol-lowering medication, slightly more than half (54.5 percent, about 47 million people) are currently taking it, meaning a substantial share of at-risk adults remain untreated.

How It Presents

Hyperlipidemia has no symptoms in the vast majority of cases. It cannot be felt, seen, or predicted based on how healthy someone looks or feels. This is precisely why routine cholesterol screening through a simple blood test is the only reliable way to detect it, rather than waiting for a symptom to prompt a doctor's visit.

In rare cases involving very high cholesterol, particularly inherited conditions like familial hypercholesterolemia, physical signs can appear, such as yellowish cholesterol deposits under the skin near the eyes or on tendons, or a grayish ring around the cornea. For most people, though, the first sign of untreated high cholesterol is a cardiovascular event itself, such as chest pain, heart attack, or stroke, which is why proactive screening matters so much.

Diagnostic Tests & Imaging

Hyperlipidemia is diagnosed with a simple blood test called a lipid panel, which measures total cholesterol, LDL, HDL, and triglycerides, typically after a period of fasting, though non-fasting panels are increasingly used. The American Heart Association and American College of Cardiology recommend adults begin cholesterol screening around age 20 and repeat it every four to six years, with more frequent testing for those with risk factors or a family history of early heart disease.


Depending on the results and a patient's individual risk profile, doctors may also calculate a 10-year cardiovascular risk score using tools like the AHA's PREVENT equations, check advanced biomarkers such as apolipoprotein B (apoB) or lipoprotein(a), or order imaging such as a coronary artery calcium (CAC) scan, a specialized CT scan that directly measures plaque buildup in the heart's arteries. These additional tools help doctors decide how aggressively to treat, especially for patients whose risk is not clear-cut from cholesterol numbers alone.

How to Treat It

When lifestyle changes are not enough, statins remain the cornerstone of drug therapy, working by reducing the liver's cholesterol production. For patients who need additional LDL lowering or cannot tolerate statins, doctors may add ezetimibe, which blocks cholesterol absorption in the gut, or PCSK9 inhibitors, a newer injectable class that can dramatically lower LDL, along with a new oral PCSK9 inhibitor that was just approved by the FDA in July 2026. Current guidelines set LDL targets based on individual risk: below 55 mg/dL for those at very high cardiovascular risk, below 70 mg/dL for many others with existing cardiovascular disease or major risk factors, and below 100 mg/dL for those at borderline risk. Surgery is not a treatment for hyperlipidemia itself, though procedures may become necessary if cholesterol-driven plaque has already caused significant artery blockages, such as stenting or bypass surgery.


On the question of muscle side effects specifically, the real number is more reassuring than its reputation suggests, and it depends heavily on how you measure it. In large randomized, placebo-controlled trials, where neither patient nor doctor knows who is taking the real drug, the true pharmacological rate of statin-associated muscle symptoms runs about 1.5% to 5% above placebo. A landmark meta-analysis pooling data from 19 trials and roughly 123,000 patients found that only about 1 in 15 muscle complaints reported by people taking a statin was actually caused by the statin itself. The rest showed up just as often in the placebo group.


That gap between the trial data and what doctors see in everyday practice, where 10% to 25% of patients report muscle aches, comes down to something researchers call the nocebo effect: expecting a side effect makes you more likely to notice and report ordinary aches and pains as drug related. Think of it like a smoke detector that is set too sensitive. It is not wrong that it beeps, but it is beeping at burnt toast far more often than an actual fire. Roughly 5% to 10% of patients do end up discontinuing a statin because of perceived muscle symptoms, even though most of those symptoms are not pharmacologically caused by the drug. This matters clinically, because stopping a statin over a symptom that was never really the statin's fault removes a proven mortality benefit for no real gain.


For patients who do experience genuine, dose-dependent muscle discomfort, coenzyme Q10 (CoQ10) supplementation is a reasonable and low-risk option to discuss with a doctor. Statins block the same liver pathway (HMG-CoA reductase) used to produce cholesterol and CoQ10, so plasma CoQ10 levels commonly drop 16% to 54% on statin therapy. Whether that drop is actually what causes muscle pain in the small subset of people who react to statins is still debated, since intramuscular CoQ10 levels do not always fall the way blood levels do. The clinical trial evidence on CoQ10 supplementation is mixed. Some meta-analyses report a modest, statistically real reduction in muscle pain scores, while at least one well-known trial (GOALS, 2015) found no benefit. CoQ10 does not meaningfully lower LDL cholesterol on its own and should never be viewed as a statin substitute; it is a possible tolerability aid, not a treatment. If a doctor and patient decide to try it, the doses used in most positive studies were 200 mg to 400 mg per day, taken with a fat-containing meal to improve absorption.

How to Prevent It

Many of the same steps used to treat high cholesterol also prevent it from developing in the first place. A diet emphasizing vegetables, fruits, whole grains, legumes, nuts, and healthy fats such as olive oil and fish, while limiting red meat, processed foods, and added sugar, has consistently been shown to support healthy cholesterol levels. Regular physical activity, maintaining a healthy weight, avoiding tobacco, and limiting alcohol all contribute meaningfully as well.

Because the 2025-2026 dyslipidemia guidelines increasingly emphasize starting healthy habits early in life, even young adults benefit from establishing these patterns well before cholesterol numbers become a problem. Routine screening, even in your twenties and thirties, allows you and your doctor to catch rising numbers early and intervene before plaque has a chance to accumulate.

Nutraceuticals: Red Yeast Rice, Citrus Bergamot, and Other Supplements"

For people who prefer to start with a non-prescription option, or who cannot tolerate statins, several supplements ("nutraceuticals" in the research literature) have real clinical trial data behind them. None of them are regulated or standardized the way prescription drugs are, so quality and dosing accuracy vary by brand. Here is what the evidence actually shows, with real numbers so you can compare them to statins and ezetimibe.


Red Yeast Rice Red yeast rice is fermented rice that naturally contains monacolin K, which is chemically identical to the active ingredient in the prescription statin lovastatin. This is why it works, and also why it carries some of the same risks as a low-dose statin. At a monacolin K dose of about 2.4 mg per day, clinical trials have recorded total cholesterol reductions around 23%, LDL reductions around 31%, and triglyceride reductions around 34%. A meta-analysis pooling more than 6,600 subjects across 20 studies found that in trials directly comparing red yeast rice to low or moderate dose statins (pravastatin 40 mg, simvastatin 10 mg, or lovastatin 20 mg), there was no statistically significant difference in LDL lowering between the two.


For context, that puts red yeast rice's LDL-lowering power in a similar range to a moderate statin dose, and meaningfully stronger than ezetimibe used alone, which typically lowers LDL by about 15% to 20% as monotherapy. Because monacolin K is pharmacologically a statin, people who experience genuine statin-associated muscle symptoms may experience the same issue with red yeast rice, and the supplement carries the same theoretical drug interaction risks. There is also a real safety wrinkle unique to the supplement form: because red yeast rice is not FDA-regulated as a drug, monacolin K content varies enormously between commercial brands, and some products have been found to contain citrinin, a fungal byproduct that can be toxic to the kidneys. Anyone considering it should treat it with the same seriousness as a prescription medication and discuss it with a doctor first, ideally choosing a third-party tested product.


Citrus Bergamot Citrus bergamot is a flavonoid-rich extract from a citrus fruit grown mostly in Southern Italy. In the foundational 2011 randomized trial of 237 people with high cholesterol, 500 mg per day of standardized bergamot polyphenolic fraction lowered total cholesterol by about 21%, LDL by about 23%, and raised HDL by about 26% over 30 days; at 1,000 mg per day the effects were larger, with LDL reductions closer to 39%. A more recent 2024 randomized trial using a lower, 150 mg per day dose over four months found smaller but still statistically significant reductions of 8.8% in total cholesterol and 11.5% in LDL. A 2024 meta-analysis pooling 14 trials found bergamot supplementation reduced LDL by an average of about 55 mg/dL and raised HDL by about 6 mg/dL.


The wide range between these numbers (11.5% in one trial, up to 39% in another) is a useful reminder that dose, formulation, and trial length all matter a great deal, and that a meaningful share of this research comes from a relatively small number of research groups, which is a limitation worth knowing about before treating any single number as gospel. Bergamot appears to be well tolerated with a favorable side effect profile in the trials conducted so far, but it has not been studied for hard outcomes like heart attack or stroke reduction, only for its effect on cholesterol numbers themselves.


Other Nutraceuticals Worth Knowing A network meta-analysis comparing multiple supplements found that, among options including artichoke, berberine, garlic, green tea extract, plant sterols and stanols, policosanol, silymarin, and spirulina, red yeast rice and bergamot consistently ranked as the two most effective for LDL and total cholesterol reduction. Plant sterols and stanols (found in fortified foods like certain margarines) typically produce more modest LDL reductions in the range of 5% to 15% at recommended intakes, but have a long track record of safety and are specifically called out in European cardiology guidelines as a reasonable add-on to lifestyle changes. Policosanol, once popular as a cholesterol supplement, was found in the same meta-analysis to have no meaningful effect on lipid levels at all, despite years of marketing suggesting otherwise. This is a good example of why it is worth checking the evidence behind a supplement rather than assuming popularity equals effectiveness.


The Bottom Line on Nutraceuticals Both red yeast rice and citrus bergamot have real, statistically significant, dose-dependent effects on LDL cholesterol, in some studies approaching what a moderate-dose statin can do. That said, the evidence base for both is smaller, shorter in duration, and far less consistent across independent research groups than the evidence behind statins, which has been tested in trials involving hundreds of thousands of patients over decades with confirmed reductions in heart attacks, strokes, and death. For someone with only mildly elevated cholesterol and low overall cardiovascular risk, a well-chosen nutraceutical alongside diet and exercise may be a reasonable starting point to discuss with a doctor. For anyone at moderate to high cardiovascular risk, or anyone who has already had a cardiovascular event, these supplements are best considered a complement to proven medical therapy rather than a replacement for it.

The Lean Mass Hyperresponder Question"

If you spend time in online health and fitness communities, you have probably run into the term "Lean Mass Hyperresponder," or LMHR. It describes a specific and fairly narrow group of people: lean, metabolically healthy individuals who, after starting a very low-carbohydrate or ketogenic diet, see their LDL cholesterol spike dramatically, sometimes to 200, 300, or even 400+ mg/dL, while their triglycerides drop and their HDL cholesterol rises. The pattern is real and has been documented in case reports and small observational cohorts. The three markers together (LDL-C generally at or above 200 mg/dL, HDL-C at or above 80 mg/dL, and triglycerides at or below 70 mg/dL) are sometimes called "the LMHR triad."


Where things get controversial is what this pattern means for cardiovascular risk. Advocates of the phenotype have argued that in this specific metabolic context, dramatically high LDL might not carry the same danger it does in the general population, since the high HDL and low triglycerides suggest an otherwise healthy metabolism. Mainstream lipidology pushes back hard on this idea. LDL particles cause atherosclerosis through a well-established, dose-dependent, and time-dependent mechanism, and decades of genetic and clinical evidence tie elevated LDL to cardiovascular risk regardless of a person's triglyceride or HDL numbers. The concern from most cardiologists and lipid specialists is that "LMHR" describes a curious pattern worth studying, not a free pass to ignore an LDL of 350.


This is also a good real-world example of why preliminary data should never be extrapolated onto the general population, which you asked us to flag directly. The most talked-about piece of "reassuring" evidence for the LMHR hypothesis was a 2025 study known as KETO-CTA, which used coronary CT angiography to track artery plaque in 100 LMHR-phenotype individuals over one year and claimed that pre-existing plaque, not high LDL, best predicted plaque progression. It was heavily promoted online as proof that LDL "doesn't matter" for this group. The study drew immediate criticism from lipid researchers over its methodology, including a shift away from its own pre-registered primary outcome, no control group for comparison, and a follow-up window (one year) far too short to capture the slow, decades-long process of atherosclerosis. In January 2026, the journal (JACC: Advances) published a formal "Expression of Concern" over the integrity of the study's data, and in March 2026 the paper was retracted outright.

The math behind why one year is not long enough is worth spelling out, since it is the kind of thing statistics can clarify better than opinion can. Atherosclerosis typically develops over 20 to 40 years. If you are trying to detect a meaningful difference in plaque progression using only 12 months of data in a group with no comparison arm, you have given yourself roughly 2% to 5% of the total disease timeline to work with, without anything to compare it against. That is like trying to judge whether a tree is going to survive a hundred-year drought by checking on it after a single rainy week.

Two threads to hold at once, and this is the balanced view for readers who are curious about this topic:

  • The LMHR pattern is a real, reproducible, and scientifically interesting phenomenon in a specific subgroup of low-carb dieters, and it deserves further, better-designed research, ideally with control groups and multi-year follow-up.

  • The claim that this pattern makes extremely high LDL harmless has no solid clinical outcomes evidence behind it right now, and the one study most often cited to support that claim has been formally retracted for data integrity concerns.

If you fit this phenotype and are considering staying on a very low-carbohydrate diet despite a very elevated LDL, that is a conversation to have directly with a cardiologist or lipid specialist, ideally one who will also look at your apoB or coronary artery calcium score, rather than a decision to make based on social media threads or a single small study.

Living With Hyperlipidemia

A high cholesterol diagnosis is not a crisis, it is useful information that lets you and your doctor take action before problems develop. Most people who manage their cholesterol well, whether through lifestyle alone or with medication, go on to live long, active, heart-healthy lives. The key is consistency: taking prescribed medications as directed, keeping regular follow-up appointments to recheck lipid panels, and sticking with the dietary and activity habits that keep numbers in range.


Think of cholesterol management like maintaining a car's engine. Regular oil changes and tune-ups do not produce dramatic, visible results day to day, but they prevent the kind of slow wear that eventually leads to a breakdown. Managing cholesterol works the same way, small consistent efforts protecting your arteries over decades rather than a single fix.

Resources

  1. Collins R et al. Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials. Lancet. 2022;400(10355):832-845.

  2. Cohen JD et al. That Myalgia of Yours Is Not From Statin Intolerance. J Am Coll Cardiol. 2021;78(14):1481-1483.

  3. Rosenson RS et al. Assessment and management of statin-associated muscle symptoms (SAMS): A clinical perspective from the National Lipid Association. J Clin Lipidol. 2022;16(6):e19-e39.

  4. Qu H et al. Effects of coenzyme Q10 supplementation on myopathy in statin-treated patients: a systematic review and meta-analysis. Curr Med Res Opin (meta-analysis, 2024 update).

  5. Littarru GP, Langsjoen P. Coenzyme Q10 and statins: biochemical and clinical implications. Biofactors. 2007;30(3):167-175. PMID: 17012968.

  6. Taylor BA et al. A randomized trial of coenzyme Q10 in patients with confirmed statin myopathy (GOALS trial). JAMA Intern Med. 2015. PMID: 25638527.

  7. Soto-Mota A, Norwitz N, Manubolu V et al. Plaque Begets Plaque. ApoB Does Not: Longitudinal Data from the KETO-CTA Trial. JACC Adv. 2025;4(7):101686. [RETRACTED, JACC Adv. 2026 May;5(5):102824]

  8. Budoff M, Manubolu VS, Kinninger A et al. Carbohydrate restriction-induced elevations in LDL-cholesterol and atherosclerosis: the KETO trial. JACC Adv. 2024;3(8):101109.

  9. Ference BA, Ginsberg HN, Graham I et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. Eur Heart J. 2017;38(32):2459-2472.

  10. Gerards MC et al. Traditional Chinese lipid-lowering agent red yeast rice results in significant LDL reduction but safety is uncertain. Atherosclerosis. 2015;240(2):415-423.

  11. Halbert SC et al. Tolerability of red yeast rice (2,400 mg twice daily) versus pravastatin (20 mg twice daily) in patients with previous statin intolerance. Am J Cardiol. 2010.

  12. Verhoeven V et al. Red yeast rice lowers cholesterol in physicians: a double blind, placebo controlled randomized trial. BMC Complement Altern Med. 2013;13:178.

  13. Mollace V et al. Hypolipemic and hypoglycaemic activity of bergamot polyphenols. Fitoterapia. 2011;82(3):309-316.

  14. Mollace R et al. Citrus bergamia Extract, a Natural Approach for Cholesterol and Lipid Metabolism Management: A Randomized, Double-Blind Placebo-Controlled Clinical Trial. Foods. 2024;13(23):3883.

  15. Mierzejewski J et al. Bergamot extract and red yeast rice in reducing high cholesterol - what is known? Quality in Sport. 2025;43:61260.

  16. Cicero AFG et al. A network meta-analysis on the comparative effect of nutraceuticals on lipid profile in adults. Pharmacol Res. 2022.

Medical Disclaimer

This article is intended for general educational purposes only and does not constitute medical advice. It is not a substitute for professional medical diagnosis, treatment, or care. Always consult your physician or a qualified healthcare provider with any questions regarding a medical condition, and never disregard professional medical advice or delay seeking it because of information read here.

 
 
 

Comments

bottom of page